- Psilocybin is seeing a “research resurgence” focused on how the substance changes the brain’s connectivity patterns
- CYBN is leading the industry in developing proprietary psychedelic-based therapeutics
- The company’s lead investigational molecule has the potential to treat major depressive disorder and alcohol use disorder
The status of psilocybin is evolving as a result of mounting public acceptance and growing evidence that the substance delivers remarkable health benefits. Cybin (NEO: CYBN) (NYSE American: CYBN) is on the leading edge of this transformation, as the clinical-stage biopharmaceutical company focuses on progressing psychedelics to therapeutics by offering a new standard of care for mental-health disorders and improving patient outcomes.
Psilocybin is undergoing a transformation. Numerous studies have reported positive findings using psilocybin “for treating depression as well as smoking and alcohol addiction, and for reducing anxiety in the terminally ill,” reported Scientific America (https://ibn.fm/Wx1Cv). “Ongoing and planned studies are testing the drug for conditions that include opioid dependence, PTSD and anorexia nervosa. This scientific interest, plus growing social acceptance, is contributing to legal changes in cities across the U.S.”
The article provided a quick overview of the history of the substance, noting that “after a flurry of research in the 1950s and 1960s, psilocybin and all other psychedelics were abruptly banned, partly in response to their embrace by the counterculture. Following the 1971 United Nations Convention on Psychotropic Substances, psilocybin was classed in the U.S. as a Schedule I substance.
The article quoted David Nutt, a neuropsychopharmacologist at Imperial College London, as saying: “It’s the worst censorship of research in history.”
This “censorship” appears to be coming to an end as Nutt and others are leading a “research resurgence” focused on how psilocybin changes the brain’s connectivity patterns, including reducing connections within the usual networks while increasing links between less connected regions. “Just this year, a study showed that treatment involving psilocybin led to sustained network alterations, which seemed to correlate with reduced depression symptoms,” the article observed. “Two organizations are beginning final rounds of trials for psilocybin’s use for depression, which could lead to the substance’s first approval by the U.S. Food and Drug Administration.”
Cybin is heavily involved in this resurgence of research. The company is leading the industry in developing proprietary psychedelic-based therapeutics, with a pipeline featuring three psychedelic molecules —CYB003, CYB004 and CYB005 — that are derived from CYBN’s novel drug-discovery platform (https://ibn.fm/4ZfwT).
Cybin’s lead investigational molecule, CYB003, is a deuterated psilocybin analog derived from psilocybin, which is part of a family of molecules called indolamines that includes more common neurotransmitters, such as serotonin. The substance is designed to achieve less variability in plasma levels, faster onset of action, shorter duration of effect and potentially better tolerability for an overall better outcome for patients. CYB003 has the potential to effectively treat major depressive disorder (“MDD”) and alcohol use disorder (“AUD”) and is currently being evaluated in a phase 1/2a clinical trial.
A deuterated dimethyltryptamine (“DMT”), CYB004 has been shown to exert its psychedelic effects by activating the 5-HT2A receptor. In its natural form, DMT is rapidly metabolized in the body, unstable and not orally bioavailable. However, preclinical studies indicate that the deuterated DMT can overcome these limitations and provide increased oral and pulmonary bioavailability, faster onset with lower doses, less patient variability, and better dose titration for fewer side effects and longer-acting desensitization of the serotonergic receptors. The company reports that CYB004, which is currently in a phase 1 in-human study, has the potential to effectively treat anxiety disorders.
The company’s third substance is CYB005, which is a discovery-phase phenethylamine derivative with the potential to effectively treat neuroinflammation and psychiatric conditions. CYB005 is in preclinical development.
For more information, visit the company’s website at www.Cybin.com.
NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN
TinyGems is your guide to the best and brightest in the under-appreciated small-cap sector. As one of 50+ brands within the InvestorBrandNetwork (“IBN”), TinyGems provides: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) enhanced press release solutions to ensure maximum impact; (4) social media distribution via IBN to reach millions of social media followers; and (5) a full array of corporate communications solutions. It’s time to uncover some of the best-kept secrets on Wall Street. TinyGems features innovative small-cap companies with huge potential, putting a spotlight on the best and brightest of these disruptors that have the technology, the talent, the drive, and the business models to make a huge impact in the markets and in portfolios. Whether it’s a game changing technology, a new more profitable product or service, or a star in a hot sector, TinyGems is the go-to source for actionable intelligence.
To receive SMS text alerts from TinyGems, text “Gems” to 844-397-5787 (U.S. Mobile Phones Only)
For more information, please visit https://www.TinyGems.com
TinyGems is part of the InvestorBrandNetwork